Details

Autor(en) / Beteiligte

• Lee, Sanghoon
• Zhao, Li
• Rojas, Christine
• Bateman, Nicholas W.
• Yao, Hui
• Lara, Olivia D.
• Celestino, Joseph
• Morgan, Margaret B.
• Nguyen, Tri V.
• Conrads, Kelly A.
• Rangel, Kelly M.
• Dood, Robert L.
• Hajek, Richard A.
• Fawcett, Gloria L.
• Chu, Randy A.
• Wilson, Katlin
• Loffredo, Jeremy L.
• Viollet, Coralie
• Jazaeri, Amir A.
• Dalgard, Clifton L.
• Mao, Xizeng
• Song, Xingzhi
• Zhou, Ming
• Hood, Brian L.
• Banskota, Nirad
• Wilkerson, Matthew D.
• Te, Jerez
• Soltis, Anthony R.
• Roman, Kristin
• Dunn, Andrew
• Cordover, David
• Eterovic, Agda Karina
• Liu, Jinsong
• Burks, Jared K.
• Baggerly, Keith A.
• Fleming, Nicole D.
• Lu, Karen H.
• Westin, Shannon N.
• Coleman, Robert L.
• Mills, Gordon B.
• Casablanca, Yovanni
• Zhang, Jianhua
• Conrads, Thomas P.
• Maxwell, George L.
• Futreal, P. Andrew
• Sood, Anil K.

Titel

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Ist Teil von

• Cell reports (Cambridge), 2020-04, Vol.31 (2), p.107502-107502, Article 107502

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC), which is the most lethal gynecologic malignancy, is not well understood. Here, we perform comprehensive multi-platform omics analyses, including integrated analysis, and immune monitoring on primary and metastatic sites from highly clinically annotated HGSC samples based on a laparoscopic triage algorithm from patients who underwent complete gross resection (R0) or received neoadjuvant chemotherapy (NACT) with excellent or poor response. We identify significant distinct molecular abnormalities and cellular changes and immune cell repertoire alterations between the groups, including a higher rate of NF1 copy number loss, and reduced chromothripsis-like patterns, higher levels of strong-binding neoantigens, and a higher number of infiltrated T cells in the R0 versus the NACT groups. [Display omitted] •High rate of NF1 loss in the R0 compared to neoadjuvant chemotherapy (NACT) group•Lower chromothripsis-like pattern and higher neoantigens in the R0 versus NACT group•Increased number of infiltrated T cells and decreased macrophages in the R0 group•Significant transcriptomic and proteomic variations between HGSC subgroups High-grade serous ovarian cancer (HGSC) patients with no gross residual disease (R0) after primary surgery have the greatest improvement in clinical outcomes. A deep understanding of molecular and cellular heterogeneity of HGSC is lacking. Findings by Lee et al. highlight major molecular and cellular differences between clinically defined subgroups of HGSC.